Amendment of the articles of association

The general meeting resolved, in accordance with the board of directors' proposal, to:

1. increase the limits for the minimum and maximum share capital so that the share capital in the Company shall be not less than SEK 176,487,500 and not more than SEK 705,950,000;
2. increase the limits for the minimum and maximum number of shares, so that the number of shares in the Company shall be not less than 28,238,000 and not more than 112,952,000 shares; and
3. increase the limit for the highest number of shares of class A which can be issued to a maximum of 81,184,250 shares and the limit for the highest number of shares of class B which can be issued to a maximum of 95,303,250 shares.

Approval of the board of directors' resolution to issue shares of class B with preferential rights for Elos Medtech's shareholders

The general meeting resolved to approve the board of directors' resolution from 12 August 2023 to increase the Company's share capital through an issue of shares with preferential rights to existing shareholders. According to the final terms set by the board of directors, as announced on 12 August 2023, each share in the Company held on the record date for participation in the rights issue, 17 October 2023, entitles to one subscription right and two subscription rights entitles to subscription for five new shares. The subscription price has been set to SEK 215 per share, which entails issue proceeds of up to approximately SEK 4,337 million before deduction of transaction costs. The subscription period will run from 20 October 2023 up to and including 3 November 2023, provided that the board of directors does not postpone the record date and thereby all related subsequent dates. Through the rights issue, the Company's share capital can be increased by a maximum of SEK 126,062,500 through the issuance of not more than 20,170,000 new shares.

More information about the resolution is available in the notice and the complete proposal included therein, which is available on the Company's website www.elosmedtech.com.

The minutes from the extraordinary general meeting, with complete decisions, will be uploaded to the Company's website.

For more information, please contact:

Stefano Alfonsi, President and CEO, +44 772 04 98 342,
email: stefano.alfonsi@elosmedtech.com

Magnus René, Chairman of the Board, +1 781 266 6957,
email: magnus.rene@mareadvisory.com

Ewa Linsäter, CFO, +76 633 32 33,
email: ewa.linsater@elosmedtech.com

For more information about Elos Medtech, please see www.elosmedtech.com.